Jacobi Capital Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $615K | Buy |
11,147
+50
| +0.5% | +$2.71K | 0.03% | 366 |
|
|
2025
Q4 | $544K | Sell |
11,097
-5
| -0% | -$233 | 0.03% | 386 |
|
|
2025
Q3 | $479K | Sell |
11,102
-44
| -0.4% | -$1.72K | 0.03% | 404 |
|
|
2025
Q2 | $428K | Buy |
11,146
+103
| +0.9% | +$3.94K | 0.03% | 419 |
|
|
2025
Q1 | $428K | Buy |
11,043
+640
| +6% | +$23.4K | 0.03% | 396 |
|
|
2024
Q4 | $352K | Buy |
10,403
+389
| +4% | +$14K | 0.03% | 427 |
|
|
2024
Q3 | $409K | Buy |
10,014
+162
| +2% | +$6.63K | 0.03% | 395 |
|
|
2024
Q2 | $379K | Sell |
9,852
-2,088
| -17% | -$87.8K | 0.03% | 363 |
|
|
2024
Q1 | $512K | Buy |
11,940
+173
| +1% | +$7.13K | 0.05% | 303 |
|
|
2023
Q4 | $436K | Sell |
11,767
-888
| -7% | -$31.9K | 0.04% | 317 |
|
|
2023
Q3 | $459K | Buy |
12,655
+1,175
| +10% | +$41.7K | 0.05% | 286 |
|
|
2023
Q2 | $409K | Buy |
11,480
+231
| +2% | +$8.29K | 0.05% | 308 |
|
|
2023
Q1 | $400K | Buy |
11,249
+731
| +7% | +$25.6K | 0.05% | 303 |
|
|
2022
Q4 | $370K | Buy |
10,518
+657
| +7% | +$21.9K | 0.05% | 307 |
|
|
2022
Q3 | $290K | Buy |
9,861
+3,602
| +58% | +$137K | 0.04% | 340 |
|
|
2022
Q2 | $341K | Sell |
6,259
-144
| -2% | -$7.95K | 0.05% | 318 |
|
|
2022
Q1 | $349K | Buy |
6,403
+168
| +3% | +$9.13K | 0.04% | 321 |
|
|
2021
Q4 | $344K | Buy |
6,235
+389
| +7% | +$20.2K | 0.04% | 329 |
|
|
2021
Q3 | $279K | Buy |
5,846
+13
| +0.2% | +$653 | 0.04% | 342 |
|
|
2021
Q2 | $290K | Buy |
5,833
+65
| +1% | +$3.12K | 0.04% | 322 |
|
|
2021
Q1 | $257K | Buy |
5,768
+180
| +3% | +$8.17K | 0.04% | 315 |
|
|
2020
Q4 | $257K | Buy |
5,588
+939
| +20% | +$43.1K | 0.04% | 295 |
|
|
2020
Q3 | $219K | Buy |
4,649
+901
| +24% | +$45.1K | 0.04% | 286 |
|
|
2020
Q2 | $191K | Buy |
3,748
+130
| +4% | +$6.67K | 0.04% | 293 |
|
|
2020
Q1 | $171K | Buy |
3,618
+1,294
| +56% | +$69K | 0.04% | 275 |
|
|
2019
Q4 | $137K | Buy |
2,324
+10
| +0.4% | +$556 | 0.03% | 329 |
|
|
2019
Q3 | $123K | Buy |
2,314
+206
| +10% | +$10.6K | 0.02% | 328 |
|
|
2019
Q2 | $105K | Buy |
2,108
+206
| +11% | +$10.3K | 0.02% | 343 |
|
|
2019
Q1 | $99K | Buy |
1,902
+325
| +21% | +$16.2K | 0.03% | 312 |
|
|
2018
Q4 | $75K | Buy |
1,577
+272
| +21% | +$13.4K | 0.02% | 336 |
|
|
2018
Q3 | $66K | Buy |
1,305
+210
| +19% | +$10.7K | 0.02% | 377 |
|
|
2018
Q2 | $55K | Buy |
1,095
+7
| +0.6% | +$353 | 0.02% | 398 |
|
|
2018
Q1 | $53K | Buy |
1,088
+6
| +0.6% | +$279 | 0.02% | 384 |
|
|
2017
Q4 | $51K | Sell |
1,082
-195
| -15% | -$9.01K | 0.02% | 370 |
|
|
2017
Q3 | $65K | Buy |
1,277
+643
| +101% | +$32.6K | 0.02% | 302 |
|
|
2017
Q2 | $33K | Buy |
634
+256
| +68% | +$13.6K | 0.01% | 368 |
|
|
2017
Q1 | $20K | Buy |
+378
| New | +$19.2K | 0.01% | 360 |
|
|
2016
Q4 | – | Sell |
-132
| Closed | -$7K | – | 646 |
|
|
2016
Q3 | $7K | Hold |
132
| – | – | ﹤0.01% | 513 |
|
|
2016
Q2 | $7K | Buy |
+132
| New | +$6.95K | ﹤0.01% | 504 |
|
Other funds holding GSK
JEST
Jacobi Capital Management's GSK Position: Q1 2026 in Review
Jacobi Capital Management increased its GSK (GSK) stake by 0.45% in Q1 2026, buying an estimated $2.71K and bringing the position to 11,147 shares worth $615K. The position accounts for 0.03% of the portfolio, ranked #366.
Jacobi Capital Management first reported a position in GSK in Q2 2016 and has held it in 39 quarters since. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.
- Jacobi Capital Management held 11,147 shares of GSK worth $615K as of Q1 2026.
- Jacobi Capital Management bought 50 GSK shares in Q1 2026, an estimated $2.71K.
- GSK made up 0.03% of Jacobi Capital Management's portfolio in Q1 2026, its #366 holding.
- Jacobi Capital Management first reported a position in GSK in Q2 2016 and has held it in 39 quarters since.
- 1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.
Based on Jacobi Capital Management's 13F filing for Q1 2026, filed 14 May 2026.